Brought to you by 
MedImmune helps Micromet develop MT103 for cancer; ends
09 Nov 2009
Executive Summary
MedImmune (drugs to treat infectious and autoimmune diseases and cancer) will help Micromet AG (antibody therapies) with the development of MT103, a B cell tumor compound that is an antibody derivative and part of a group of candidates called Bi-Specific T Cell Engagers (BiTE).
Deal Industry
- Pharmaceuticals
-
Biotechnology
- Drug Discovery Tools
-
Large Molecule
- Antibodies
Deal Status
- Terminated
Deal Type
-
Alliance
- Co-Promotion
- Includes Equity
- Includes Royalty or Profit Split Information
- Intra-Biotech Deal
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
MedImmune helps Micromet develop MT103 for cancer; ends
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice